Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes
Diabetes Research and Clinical Practice Feb 17, 2018
Wang JS, et al. - The association of difference between observed and predicted glycated hemoglobin (dopHbA1c) and HbA1c reduction after vildagliptin-based oral therapy was examined in patients with type 2 diabetes (T2D). After shifting to vildagliptin-based dual oral therapy, a higher baseline dopHbA1c was associated with a greater HbA1c reduction in T2D patients with an HbA1c ≧7%.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
